Biohaven has licensed its Kv7 platform and lead epilepsy candidate, opakalim, to SK Biopharmaceuticals for up to $795 million, including $400 million upfront. This deal provides Biohaven with significant non-dilutive capital and an established commercialization path for opakalim, while SK Biopharmaceuticals gains a promising late-stage epilepsy drug.
Biohaven has entered into a licensing agreement with SK Biopharmaceuticals for its Kv7 platform and the epilepsy candidate opakalim. This is a major positive catalyst for Biohaven as it secures up to $795 million, with a substantial $400 million upfront payment, providing significant non-dilutive capital and strengthening its balance sheet. The deal also leverages SK Biopharmaceuticals' proven commercial capabilities, giving opakalim an established path to market without Biohaven incurring the costs of building its own infrastructure. For SK Biopharmaceuticals, this represents an opportunity to expand its epilepsy portfolio with a next-generation drug in late-stage development. Short-term, Biohaven's stock is likely to react positively due to the cash infusion and validation of its pipeline. Long-term, the success of opakalim and the realization of milestone payments and royalties will be key for Biohaven, while SK Biopharmaceuticals' ability to successfully commercialize opakalim will be crucial.